Moderate hot flushes and sleep problems, milder mood and urogenital symptoms
Somatic-vegetative
6 of 16
Psychological
5 of 16
Urogenital
2 of 12
The MRS measures symptom burden over four weeks. It does not diagnose menopause, which is a clinical call.
Run your own numbers in the tool above.
Chapter 01 · The scoring
How the 11 items are scored
The MRS was originally developed in Germany in the early 1990s, then standardized into its international form by Heinemann, Potthoff, and Schneider in a 2003 paper that compared its psychometric properties across 16 countries.1 It is now one of the most widely used patient-reported outcome measures for menopausal symptom severity, free for clinical and research use, and translated into more than 25 languages.
*6 month plan, billed once for the term when a physician approves. Renews each term.
Each item is rated on a 5-point scale from 0 (no symptoms) to 4 (very severe). The 11 items group into three clinically meaningful subscales: somatic-vegetative (4 items covering hot flushes, heart discomfort, sleep, and joint or muscle pain), psychological (4 items covering depressive mood, irritability, anxiety, and physical or mental exhaustion), and urogenital (3 items covering sexual problems, bladder problems, and vaginal dryness). The total MRS score is the sum of all 11 items, with a maximum of 44.
Total score band
Severity
What it suggests
16 or higher
Severe
Strong clinician evaluation suggested
9 to 15
Moderate
Evaluation often benefits
5 to 8
Mild
Visit reasonable if daily life is affected
0 to 4
Minimal
Preventive discussion still useful
Total-score severity bands from the 2003 international validation. Score thresholds follow Heinemann et al. 2003.
Chapter 02 · The pattern
Why subscales matter more than the total
A total score of 12 from one woman with predominantly somatic-vegetative symptoms (hot flushes, sleep) is a different clinical picture from a total score of 12 from another woman whose symptoms are mostly urogenital (vaginal dryness, bladder issues). Treatment choices diverge. Systemic hormone therapy is most effective for vasomotor symptoms, while low-dose vaginal estrogen is often the first-line option for genitourinary symptoms of menopause and carries a different risk profile. The MRS subscales surface this distribution and let a clinician focus the visit on what is actually bothering you.
Start here · one question
How long have you been experiencing menopause symptoms?
Tap an answer to start your hormone therapy intake. You can change it there.
Subscale
Items covered
Max points
Somatic-vegetative
Hot flushes, heart discomfort, sleep, joint and muscle pain
Sexual problems, bladder problems, vaginal dryness
12
A severe per-subscale score on its own can warrant clinician attention even with a low total.
Chapter 03 · The fine print
What the MRS does not do
The MRS is a screener and a tracking tool. It does not diagnose menopause, exclude other causes of similar symptoms (thyroid disease, depression, sleep disorders, medication side effects), or determine whether a specific treatment is right for you. Menopause itself is diagnosed clinically as 12 consecutive months without a menstrual period in women with intact uterus and ovaries; perimenopause is identified by symptoms and menstrual irregularity in the years leading up to that point. The cited severity thresholds are population-based; an individual's symptom impact can be higher or lower than the band suggests. Individual results vary.
For vasomotor symptoms (hot flushes, night sweats), systemic hormone therapy remains the most effective option in appropriately selected women, per the 2022 NAMS position statement.2 Non-hormonal options include low-dose paroxetine (the only FDA-approved non-hormonal medication for vasomotor symptoms), gabapentin, oxybutynin, and the newer NK3 receptor antagonist fezolinetant. For genitourinary symptoms, low-dose vaginal estrogen is highly effective with a different risk profile. The right combination depends on your symptom pattern, age, time since menopause, personal and family history, and preferences.
Your score is a starting point for a conversation, not a diagnosis. A clinician interprets it alongside your history to decide what, if anything, to treat.
Frequently asked questions
Every medication on sipra is prescribed by a licensed physician, so your care always starts with a visit. Your sipra membership gives you ongoing access to those physician visits, so you can check in, adjust your plan, and ask questions whenever you need, without paying per visit. It is how we keep high-quality care convenient: one membership, physician access whenever you need it, and support at every step.
The MRS quantifies how much menopausal symptoms have affected you in the past four weeks. It does not diagnose menopause or rule out other causes. A score between 9 and 15 is considered moderate; 16 or higher is severe. Per-subscale scores show where symptoms cluster (somatic, psychological, or urogenital), which helps a clinician focus treatment. Individual results vary.
No. The MRS measures symptom burden, not menopause status. Menopause is defined clinically as 12 consecutive months without a menstrual period, and the diagnosis is made by a clinician with your full history. The MRS is a tracking tool you can use before, during, and after treatment.
The MRS was developed by a German research group in the 1990s and standardized in its international form by Heinemann, Potthoff, and Schneider in 2003 (Health and Quality of Life Outcomes, 1:28). It has been validated across 16 countries and translated into more than 25 languages. It is free for clinical and research use.
Evidence-supported options include hormone therapy (estrogen with or without progesterone depending on whether you have a uterus), non-hormonal prescription medications such as low-dose paroxetine or fezolinetant for hot flashes, vaginal estrogen for genitourinary symptoms, and behavioral interventions for sleep and mood. A sipra physician evaluates your full history and discusses which options fit your risk profile. Individual results vary.
Heinemann LAJ, Potthoff P, Schneider HPG. "International versions of the Menopause Rating Scale (MRS)." Health and Quality of Life Outcomes. 2003;1:28. doi.org
"The 2022 Hormone Therapy Position Statement of The North American Menopause Society." Menopause. 2022;29(7):767-794. doi.org
Heinemann K, Ruebig A, Potthoff P, et al. "The Menopause Rating Scale (MRS): a methodological review." Health and Quality of Life Outcomes. 2004;2:45. doi.org
Screener, not a diagnosis. The MRS measures symptom burden over the past four weeks. A licensed physician evaluates causes and treatment options. Individual results vary. Last reviewed June 10, 2026 by Jillian Foglesong Stabile, MD, FAAFP, DABOM. Prices snapshot 11-item validated screener.
Compounded medications are not FDA-approved and require a patient-specific prescription. Brand names are trademarks of their owners; sipra is not affiliated with them.
Your Privacy Choices
We use analytics and advertising cookies to see what helps people most. You can decline them at any time. Health and genetic information is never shared with third parties. Read our Privacy Policy.